It was unknown whether the use of Oncotype DX test in women with HR+, HER2− breast cancer and 1–3 nodes positive treated by the UK National Health Service (NHS) would lead to a reduction in use of chemotherapy and whether it would increase or decrease confidence in the use or avoidance of chemotherapy for oncologists and patients. This evidence concerns the gene ERBB2 and breast cancer.